Cargando…

The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada

This article identifies the potential sources of inequity in three stages of integrating cystic fibrosis personalized medicines into the Canadian healthcare system and proposes mitigating strategies: (1) clinical research and diagnostic testing; (2) regulatory oversight and market authorization; and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shemie, Genevieve, Nguyen, Minh Thu, Wallenburg, John, Ratjen, Felix, Knoppers, Bartha Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151662/
https://www.ncbi.nlm.nih.gov/pubmed/34067090
http://dx.doi.org/10.3390/jpm11050382
_version_ 1783698436088922112
author Shemie, Genevieve
Nguyen, Minh Thu
Wallenburg, John
Ratjen, Felix
Knoppers, Bartha Maria
author_facet Shemie, Genevieve
Nguyen, Minh Thu
Wallenburg, John
Ratjen, Felix
Knoppers, Bartha Maria
author_sort Shemie, Genevieve
collection PubMed
description This article identifies the potential sources of inequity in three stages of integrating cystic fibrosis personalized medicines into the Canadian healthcare system and proposes mitigating strategies: (1) clinical research and diagnostic testing; (2) regulatory oversight and market authorization; and (3) implementation into the healthcare system. There is concern that differential access will cast a dark shadow over personalized medicine by stratifying the care that groups of patients will receive—not only based on their genetic profiles, but also on the basis of their socioeconomic status. Furthermore, there is a need to re-evaluate regulatory and market approval mechanisms to accommodate the unique nature of personalized medicines. Physical and financial accessibility ought to be remedied before personalized medicines can be equitably delivered to patients. This article identifies the socio–ethical and legal challenges at each stage and recommends mitigating policy solutions.
format Online
Article
Text
id pubmed-8151662
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81516622021-05-27 The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada Shemie, Genevieve Nguyen, Minh Thu Wallenburg, John Ratjen, Felix Knoppers, Bartha Maria J Pers Med Review This article identifies the potential sources of inequity in three stages of integrating cystic fibrosis personalized medicines into the Canadian healthcare system and proposes mitigating strategies: (1) clinical research and diagnostic testing; (2) regulatory oversight and market authorization; and (3) implementation into the healthcare system. There is concern that differential access will cast a dark shadow over personalized medicine by stratifying the care that groups of patients will receive—not only based on their genetic profiles, but also on the basis of their socioeconomic status. Furthermore, there is a need to re-evaluate regulatory and market approval mechanisms to accommodate the unique nature of personalized medicines. Physical and financial accessibility ought to be remedied before personalized medicines can be equitably delivered to patients. This article identifies the socio–ethical and legal challenges at each stage and recommends mitigating policy solutions. MDPI 2021-05-07 /pmc/articles/PMC8151662/ /pubmed/34067090 http://dx.doi.org/10.3390/jpm11050382 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Shemie, Genevieve
Nguyen, Minh Thu
Wallenburg, John
Ratjen, Felix
Knoppers, Bartha Maria
The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
title The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
title_full The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
title_fullStr The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
title_full_unstemmed The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
title_short The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
title_sort equitable implementation of cystic fibrosis personalized medicines in canada
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151662/
https://www.ncbi.nlm.nih.gov/pubmed/34067090
http://dx.doi.org/10.3390/jpm11050382
work_keys_str_mv AT shemiegenevieve theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT nguyenminhthu theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT wallenburgjohn theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT ratjenfelix theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT knoppersbarthamaria theequitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT shemiegenevieve equitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT nguyenminhthu equitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT wallenburgjohn equitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT ratjenfelix equitableimplementationofcysticfibrosispersonalizedmedicinesincanada
AT knoppersbarthamaria equitableimplementationofcysticfibrosispersonalizedmedicinesincanada